Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Aclaris Therapeutics Inc buy melinda

Start price
€18.73
04.02.18 / 50%
Target price
€20.57
26.03.18
Performance (%)
-18.15%
End price
€15.33
26.03.18
Summary
This prediction ended on 26.03.18 with a price of €15.33. The prediction for Aclaris Therapeutics Inc disappointed with a performance of -18.15%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Aclaris Therapeutics Inc -3.424% -3.424% -86.497% -94.941%
iShares Core DAX® 1.051% -1.833% 12.822% 15.392%
iShares Nasdaq 100 -0.547% -3.738% 40.625% 42.396%
iShares Nikkei 225® -1.778% -8.115% 16.092% 0.891%
iShares S&P 500 0.002% -2.226% 28.387% 41.095%

According to melinda what are the pros and cons of Aclaris Therapeutics Inc for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Aclaris Therapeutics Inc diskutieren
Prediction Buy
Perf. (%) -18.15%
Target price 20.566
Change
Ends at 26.03.18

Biotechnologie und Medizintechnik SecteurRecherche Agenda 14/02 | 21.30 Präsentation



Beruf
Produziert und entwickelt neue dermatologischen Therapien

Aclaris Therapeutics, Inc. ist ein pharmazeutisches Unternehmen , das klinische Stadium Spezialität zur Identifizierung, Entwicklung und Vermarktung neuartiger Medikamente spezialisiert auf unerfüllte Bedürfnisse in der Dermatologie zu adressieren.

Das Unternehmen verfolgt auch die Entwicklung von topischen Mitteln für die Behandlung und Prävention einer Reihe von medizinischen und kosmetischen Indikationen.

Das Unternehmen wurde von Neal S. Walker, Frank Ruffo, Kamil Ali Jackson, Christopher V. Powala und Stuart D. Shanler im Juni 2012 gegründet und befindet sich in Malvern, PA ansässig.

Anzahl der Mitarbeiter: 31 Personen.



Prediction Buy
Perf. (%) -18.15%
Target price 20.566
Change
Ends at 26.03.18

(Vom Mitglied beendet)

Stopped prediction by melinda for Aclaris Therapeutics Inc

buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€5.05
06.11.23
€6.00
06.11.24
-81.19%
10.12.23

Could be worthwhile Investment >10% per year
buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€11.54
21.02.22
€15.00
21.02.23
2.90%
22.02.23

Could be worthwhile Investment >10% per year
buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€1.43
23.06.20
€1.60
04.11.21
913.99%
05.11.21

Could be worthwhile Investment >10% per year
buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€5.60
19.01.19
€8.12
30.10.19
-70.19%
30.10.19

Could be worthwhile Investment >10% per year
buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€14.25
17.08.18
€18.31
03.12.18
-40.25%
03.12.18

Could be worthwhile Investment >10% per year
buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€23.91
04.10.17
€27.06
19.12.17
-9.54%
19.12.17

Could be worthwhile Investment >10% per year
buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€29.29
07.03.17
€30.67
07.09.17
-18.57%
07.09.17

Could be worthwhile Investment >10% per year
buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€25.29
21.02.17
€27.06
24.02.17
7.13%
24.02.17

Could be worthwhile Investment >10% per year
buy
Aclaris Therapeutics Inc

Start price
Target price
Perf. (%)
€18.34
10.07.16
€19.84
29.08.16
8.36%
29.08.16

Could be worthwhile Investment >10% per year